Pharma News

Leading drugmaker Dr Reddy's Laboratories today acknowledged having received a warning letter from the US FDA relating to its three manufacturing plants in Andhra Pradesh and Telangana.

Widely thought to be essential for good health, Omega 3 fatty acid supplements may not be of much help in treating major depressive disorders, suggests new research.

(Business Wire India); Piramal Enterprises’ Consumer Products Division announces the acquisition of the baby-care brand “Little’s”, which includes the entire product range across six categories.

Premature ejaculation including female sexual dysfunction should not be classified as an illness, argue researchers, adding that the illness factor may have been constructed by sexual medicine experts under the influence of drug companies.

Once they enter memory, depressive thoughts can linger for long in affected people, and this extended duration may reduce the amount of information that these individuals can remember, suggests new research.

[adsense:336x280:8701650588]

 Like HIV and Ebola, the hepatitis A virus is of likely animal origin, finds a large-scale study looking into the evolutionary origins of the global pathogen.

Particulate matter and nitric dioxide emissions from industrial plants or vehicles increase the risk of heart attacks, despite being within 'safe' levels of air pollution, a new study has claimed. The study examined the effect of short term exposure to air pollution on the risk of ST-segment elevation myocardial infarction (STEMI). This type of myocardial infarction (heart attack) has the worst prognosis and is caused by thrombotic occlusion of a coronary artery that damages the heart.

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) were comparable in maintaining viral suppression rates to a three drug oral regimen of investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs). The 32 week results of LATTE 2 will be presented at a forthcoming scientific conference. ViiV Healthcare and Janssen Sciences Ireland UC (Janssen) are collaborating to conduct LATTE 2.

Merck Serono has signed a collaboration with Polish biotechnology firm Selvita to jointly discover small molecule based drugs targeting proteins involved in cancer cell metabolism.